Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Dragana NikolicManfredi Rizzo

Abstract

Liraglutide has several non-glycemic effects, including those on plasma lipids and lipoproteins, contributing to its cardiovascular benefit; however, the exact underlying mechanisms remain unclear. We investigated a novel anti-atherogenic effect of liraglutide in a real-world prospective study on patients with type 2 diabetes (T2DM). Sixty-two patients with T2DM (31 men, 31 women; mean age ± standard deviation 61 ± 9 years) naïve to incretin-based therapies were treated with liraglutide (1.2 mg/day) as add-on therapy to metformin (1500-3000 mg/day) for 4 months. Laboratory analyses included the assessment of lipoprotein subclass profile by gel electrophoresis (Lipoprint; Quantimetrix Corp., Redondo Beach, CA, USA). Carotid intima-media thickness (cIMT) was assessed by Doppler ultrasonography. Statistical analyses included the paired t test, Spearman correlation and multiple regression analysis. The addition of liraglutide to metformin monotherapy resulted in significant reductions in fasting glycemia, hemoglobin A1c, body mass index, waist circumference, total cholesterol, triglycerides and low-density lipoprotein (LDL)-cholesterol, as well as in cIMT. There was an increase in the large LDL-1 subfraction, with a concomitant red...Continue Reading

Associated Clinical Trials

References

Dec 8, 2004·The Journal of Clinical Endocrinology and Metabolism·G SchernthanerUNKNOWN Quartet [corrected] Study Group
Jun 16, 2006·Cardiovascular Drugs and Therapy·Manfredi Rizzo, Kaspar Berneis
Sep 14, 2007·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·M RizzoK Berneis
Dec 3, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·M RizzoM Arslan
Apr 21, 2009·Translational Research : the Journal of Laboratory and Clinical Medicine·Manfredi RizzoJelena Vekic
Jan 26, 2010·Metabolism: Clinical and Experimental·Julia H GoedeckeSteven E Kahn
Jan 19, 2012·Current Vascular Pharmacology·Michael S KostapanosDimitri P Mikhailidis
Jul 3, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·T A WaddenUNKNOWN NN8022-1923 Investigators
Aug 28, 2013·The Journal of Clinical Endocrinology and Metabolism·R GoldbergE Barrett-Connor
May 21, 2014·Best Practice & Research. Clinical Endocrinology & Metabolism·Marcin BarylskiGiuseppe Montalto
May 21, 2014·Journal of Diabetes Investigation·Alireza EsteghamatiManouchehr Nakhjavani
Nov 14, 2014·The Journal of Clinical Endocrinology and Metabolism·Manfredi RizzoGiovanni Li Volti
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jan 18, 2017·Diabetes, Obesity & Metabolism·Manfredi RizzoGiorgio Sesti
Feb 9, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sarah J HallbergJeff S Volek
Mar 18, 2019·International Journal of Cardiology·Domenico CianfloneManfredi Rizzo

❮ Previous
Next ❯

Citations

May 1, 2021·International Journal of Molecular Sciences·Rosaria Vincenza GiglioManfredi Rizzo
Aug 2, 2021·Metabolism: Clinical and Experimental·Manfredi RizzoChristos S Mantzoros
Sep 19, 2021·Scientific Reports·Emilie H ZobelJoachim Størling

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis

Clinical Trials Mentioned

NCT01715428

Software Mentioned

SPSS
ScanWizard Pro

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

Expert Review of Endocrinology & Metabolism
Francisco Javier Ampudia-BlascoManel Puig Domingo
Journal of the Indian Medical Association
Manash P BaruahMala Dharmalingam
Nihon rinsho. Japanese journal of clinical medicine
Tomono Takahashi, Masato Odawara
© 2021 Meta ULC. All rights reserved